Ad is loading...
AVUGX
Price
$8.72
Change
-$0.00 (-0.00%)
Updated
Nov 15 closing price
VIVAX
Price
$68.72
Change
-$0.00 (-0.00%)
Updated
Nov 15 closing price
Ad is loading...

AVUGX vs VIVAX

Header iconAVUGX vs VIVAX Comparison
Open Charts AVUGX vs VIVAXBanner chart's image
American Century Value R5
Price$8.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index I
Price$68.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
AVUGX vs VIVAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AVUGX vs. VIVAX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVUGX is a Buy and VIVAX is a Buy.

FUNDAMENTALS
Fundamentals
VIVAX has more cash in the bank: 184B vs. AVUGX (2.24B). VIVAX (2.25) and AVUGX (2.16) have matching dividends . AVUGX was incepted earlier than VIVAX: AVUGX (8 years) vs VIVAX (32 years). AVUGX is a more actively managed with annual turnover of: 42.00 vs. VIVAX (10.00). AVUGX has a lower initial minimum investment than VIVAX: AVUGX (0) vs VIVAX (3000). VIVAX annual gain was more profitable for investors over the last year : 25.55 vs. AVUGX (15.62). VIVAX return over 5 years is better than : 50.81 vs. AVUGX (18.00).
AVUGXVIVAXAVUGX / VIVAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years32 years-
Gain YTD12.91317.91272%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets2.24B184B1%
Annual Yield % from dividends2.162.2596%
Returns for 1 year15.6225.5561%
Returns for 3 years-7.6621.58-36%
Returns for 5 years18.0050.8135%
Returns for 10 yearsN/A110.46-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LI22.720.49
+2.20%
Li Auto
ICCC3.610.01
+0.28%
ImmuCell Corp
BXC120.39-0.95
-0.78%
BlueLinx Holdings
LNTH76.83-4.01
-4.96%
Lantheus Holdings
PSTX2.76-0.45
-14.02%
Poseida Therapeutics